The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
High-Dose Pancreatic-Enzyme Supplements and Fibrosing Colonopathy in Children with Cystic Fibrosis
Open accessAbstract
BACKGROUND: Fibrosing colonopathy has been reported in young children with cystic fibrosis, the majority of whom take high-strength pancreatic-enzyme supplements to control intestinal malabsorption. We conducted a case-control study in the United States to investigate the relation between dose and type of pancreatic-enzyme supplement and fibrosing colonopathy. METHODS: Children with histopathologically confirmed cases of fibrosing colonopathy who required colectomy for colonic strictures from January 1, 1990, through December 31, 1994, were identified. Each of these patients was matched according to age at the time of surgery and medical center with up to four controls with cystic fibrosis who did not have fibrosing colonopathy. RESULTS: We studied 29 patients (mean age, 5.0 years) with fibrosing colonopathy (case patients) and 105 controls (mean age, 5.2 years). The mean dose of pancreatic-enzyme supplement was 50,046 units of lipase per kilogram of body weight per day for the case patients and 18,985 units per kilogram per day for the controls. A history of gastrointestinal complications attributed to cystic fibrosis and the use of histamine H2-receptor blockers, corticosteroids, or recombinant human DNase (dornase alfa) were associated with a higher incidence of fibrosing colonopathy. After adjustment for a history of such complications and the use of these medicines, the relative risk of fibrosing colonopathy that was associated with a dose of 24,001 to 50,000 units of lipase per kilogram per day, as compared with a dose of 0 to 24,000 units per kilogram per day, was 10.9 (95 percent confidence interval, 1.6 to 71.8), and that associated with a dose of more than 50,000 units per kilogram per day was 199.5 (95 percent confidence interval, 9.9 to 4026.0). The strength, coating, and manufacturer of the products used were not associated with the risk of fibrosing colonopathy. CONCLUSIONS: In young children with cystic fibrosis, we found a strong relation between high daily doses of pancreatic-enzyme supplements and the development of fibrosing colonopathy. Our findings support recommendations that the daily dose of pancreatic enzymes for most patients should remain below 10,000 units of lipase per kilogram.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dose-Response and Trend Analysis in Epidemiology: Alternatives to Categorical Analysis
Greenland, S. (1995) · Epidemiology · doi:10.1097/00001648-199507000-00005 · Cited by 1,085
The changing epidemiology of cystic fibrosis
FitzSimmons, S. C. (1993) · The Journal of Pediatrics · doi:10.1016/s0022-3476(05)83478-x · Cited by 928
Self-citationStrictures of ascending colon in cystic fibrosis and high-strength pancreatic enzymes
Smyth, R. L., Smyth, A. R., Lloyd, D. A., van Velzen, D., & Heaf, D. P. (1994) · The Lancet · doi:10.1016/s0140-6736(94)90817-6 · Cited by 279
High-strength pancreatic enzyme supplements and large-bowel stricture in cystic fibrosis
OADES, P. J., Bush, A., Ong, P. S., Brereton, R., Campbell, C. A., Forrest, J. R., Musgrove, C., Taylor, C. J., & Dodge, J. A. (1994) · The Lancet · doi:10.1016/s0140-6736(94)90836-2 · Cited by 53
Cited by
Consensus Report on Nutrition for Pediatric Patients With Cystic Fibrosis
Borowitz, D., Baker, R. D., & Stallings, V. (2002) · Journal of Pediatric Gastroenterology and Nutrition · doi:10.1002/j.1536-4801.2002.tb07816.x · Cited by 581
Self-citationYankaskas, J. R., Marshall, B. C., Sufian, B., Simon, R. H., & Rodman, D. (2004) · Chest · doi:10.1378/chest.125.1_suppl.1s · Cited by 579
Zaroff, J. G., Rosengard, B. R., Armstrong, W. F., Babcock, W. D., D’Alessandro, A., Dec, G. W., Edwards, N. M., Higgins, R. S., Jeevanandum, V., Kauffman, M., et al. (2002) · Circulation · doi:10.1161/01.cir.0000025587.40373.75 · Cited by 495
Nutrition in patients with cystic fibrosis: a European Consensus
Sinaasappel, M., Stern, M., Littlewood, J., Wolfe, S., Steinkamp, G., Heijerman, H. G. M., Robberecht, E., & Döring, G. (2002) · Journal of Cystic Fibrosis · doi:10.1016/s1569-1993(02)00032-2 · Cited by 477
Cystic Fibrosis Foundation Evidence-Based Guidelines for Management of Infants with Cystic Fibrosis
Borowitz, D., Robinson, K. A., Rosenfeld, M., Davis, S. D., Sabadosa, K. A., Spear, S. L., Michel, S. H., Parad, R. B., White, T. B., Farrell, P. M., et al. (2009) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2009.09.001 · Cited by 456
Self-citation
Metadata
- Authors
- FitzSimmons, S. C., Burkhart, G. A., Borowitz, D., Grand, R. J., Hammerstrom, T., Durie, P. R., Lloyd-Still, J. D., & Lowenfels, A. B.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 1997-05
- Volume
- 336
- Issue
- 18
- Pages
- 1283-1289
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2325591522
- Cited by
- 317
- References
- 4
- FWCI
- 16.80
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: High-Dose Pancreatic-Enzyme Supplements and Fibrosing Colonopathy in Children with Cystic Fibrosis. https://app.cochat.ai/papers/10.1056/nejm199705013361803
- The paper
- FitzSimmons, S. C., Burkhart, G. A., Borowitz, D., Grand, R. J., Hammerstrom, T., Durie, P. R., Lloyd-Still, J. D., & Lowenfels, A. B. (1997). High-Dose Pancreatic-Enzyme Supplements and Fibrosing Colonopathy in Children with Cystic Fibrosis. New England Journal of Medicine. https://doi.org/10.1056/nejm199705013361803
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.